statistiche ricercatore

Continente	#
AS - Asia	593
NA - Nord America	417
EU - Europa	288
AF - Africa	40
Continente sconosciuto - Info sul continente non disponibili	27
SA - Sud America	24
OC - Oceania	2
Totale	1.391

Nazione	#
US - Stati Uniti d'America	408
VN - Vietnam	188
SG - Singapore	148
CN - Cina	116
IT - Italia	92
HK - Hong Kong	60
SE - Svezia	38
DE - Germania	36
GB - Regno Unito	26
IN - India	23
BD - Bangladesh	21
BR - Brasile	19
CI - Costa d'Avorio	16
FI - Finlandia	15
IE - Irlanda	15
NL - Olanda	15
TG - Togo	11
CH - Svizzera	10
FR - Francia	10
BG - Bulgaria	8
JP - Giappone	8
RU - Federazione Russa	7
CA - Canada	6
ES - Italia	5
EG - Egitto	4
JO - Giordania	4
TH - Thailandia	4
TR - Turchia	4
KR - Corea	3
NG - Nigeria	3
AR - Argentina	2
AU - Australia	2
BE - Belgio	2
GR - Grecia	2
ID - Indonesia	2
IQ - Iraq	2
LB - Libano	2
LT - Lituania	2
MA - Marocco	2
SC - Seychelles	2
TW - Taiwan	2
ZA - Sudafrica	2
AT - Austria	1
BA - Bosnia-Erzegovina	1
DK - Danimarca	1
EC - Ecuador	1
GP - Guadalupe	1
HR - Croazia	1
KG - Kirghizistan	1
MY - Malesia	1
NI - Nicaragua	1
PH - Filippine	1
PK - Pakistan	1
PL - Polonia	1
PR - Porto Rico	1
PY - Paraguay	1
SA - Arabia Saudita	1
UZ - Uzbekistan	1
VE - Venezuela	1
XK - ???statistics.table.value.countryCode.XK???	1
Totale	1.365

Nome	#
Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors	199
The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players?	196
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma	188
Single-agent carboplatin in extensive disease small-cell lung cancer patient with liver failure: A case report within the experience of a single institution	183
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies	165
Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System	162
Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible?	148
PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: The role of salvage chemo-immunotherapy combination	89
Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: Rationale and clinical implication	61
Totale	1.391

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	104	0	0	3	4	9	4	3	13	20	5	31	12
2022/2023	137	6	16	8	7	5	8	10	8	29	11	12	17
2023/2024	56	6	6	1	6	2	13	3	4	2	5	8	0
2024/2025	249	25	22	28	14	40	9	27	13	0	17	15	39
2025/2026	698	60	108	34	48	60	38	97	29	107	50	24	43
2026/2027	26	15	11	0	0	0	0	0	0	0	0	0	0
Totale													1.391

CRIS Current Research Information System